NYSE Shariah screener · October 2026

Is AstraZeneca PLC (AZN) Halal?

PASS

AstraZeneca PLC · NYSE: AZN · Healthcare

The short answer

Yes - AstraZeneca PLC (AZN) passes this Shariah stock screen at all three gates. AstraZeneca, the Cambridge-based biopharmaceutical company, earns 100% of its revenue from prescription medicines across oncology, cardiovascular/renal/metabolism, respiratory/immunology, rare disease, and vaccines (FY2025 revenue $58,739m) - none of which involve alcohol, tobacco, gambling, weapons, adult entertainment, pork, or conventional finance. The financial ratios pass: interest-bearing debt of $27,819m is about 11.1% of its ~$250.4B market cap ($157.70/share, October 2, 2026), below the ~33% ceiling, and finance income of $360m is about 0.61% of revenue, below the 5% ceiling. Zoya and Musaffa independently rate AstraZeneca Shariah-compliant / halal. This is a factual screen, not a religious ruling - consult a qualified scholar for personal rulings.

Gate 1 — Business activity: PASS

AstraZeneca PLC (NYSE: AZN), headquartered in Cambridge, England, is a global, science-led biopharmaceutical company. Per its Form 20-F 'Annual Report & Form 20-F Information 2025' (filed with the SEC February 24, 2026; Commission File No. 001-11960), FY2025 revenue by therapy area was: Oncology (Tagrisso, Imfinzi, Lynparza, Enhertu - the core growth driver); BioPharmaceuticals - Cardiovascular, Renal and Metabolism ($12,861m) and Respiratory and Immunology ($8,866m; Breztri, Fasenra, Tezspire, Saphnelo); Rare Disease (via Alexion); and Vaccines and Immune Therapies ($1,268m; FluMist, Beyfortus), on total revenue of $58,739m (+9%). Business-screen implication (factual): 100% prescription-medicine revenue - no alcohol, tobacco, gambling, weapons, adult entertainment, pork, or conventional-finance segments are disclosed. Context only: in 2021 Indonesia's Ulema Council raised a pork-trypsin concern about the COVID-19 vaccine; AstraZeneca denied any animal-derived content and Darul Iftaa (Malawi) issued a finding of permissibility - no current Shariah-screening flag arises from this. Gate 1 passes. Facts only.

Gate 2 — Debt and cash: PASS

Per AstraZeneca's FY2025 Form 20-F (fiscal year ended December 31, 2025), interest-bearing loans and borrowings were $3,104m (current) plus $24,715m (non-current) = $27,819m total (Note 19). Against a market cap of about $250.4B (quoted September 30, 2026; cross-check: $157.70 x about 1.55 billion ordinary shares in issue = about $244B, October 2, 2026), debt / market cap is about 11.1% - below the ~33% ceiling. Cash and cash equivalents of $5,711m plus other investments ($30m + $2,223m) = $7,964m of cash/securities, about 3.2% of market cap. Gate 2 passes. Facts only.

Gate 3 — Non-compliant income: PASS

AstraZeneca's FY2025 Form 20-F reports finance income of $360m (2024: $458m; 2023: $344m) - returns on deposits and equity securities plus interest on tax balances (Note 4). $360m / FY2025 total revenue of $58,739m = about 0.61% of revenue - below the 5% non-compliant income ceiling. Third-party screener Zoya independently reports the same $360m figure at 0.61% of revenue. Gate 3 passes. Facts only.

Key figures used

Business: global biopharmaceuticals - Oncology (Tagrisso, Imfinzi, Lynparza, Enhertu); BioPharma CVRM $12,861m and R&I $8,866m; Rare Disease (Alexion); Vaccines & Immune Therapies $1,268m; HQ Cambridge, England
FY2025: total revenue $58,739m (+9%); finance income $360m; dividend $3.20/share (FY2025), planned $3.30 (FY2026)
Debt: $27,819m interest-bearing loans and borrowings ($3,104m current + $24,715m non-current, FY2025 20-F) - about 11.1% of ~$250.4B market cap, below the ~33% ceiling
Cash: $5,711m cash and cash equivalents + $2,253m other investments = $7,964m cash/securities - about 3.2% of market cap
Finance income: $360m - about 0.61% of $58,739m revenue, below the 5% ceiling (Zoya reports the same figure)
No haram segments: 100% prescription-medicine revenue - no alcohol, tobacco, gambling, weapons, adult entertainment, pork, or conventional finance
Third-party screeners: Zoya says Shariah-compliant (Sep 2026); Musaffa classifies halal (AAOIFI); ShariaPortfolio - no coverage found
Material: direct listing of $0.25 ordinary shares on NYSE Feb 2, 2026 (ticker AZN retained; Nasdaq ADS delisted Jan 30, 2026; ADR programme terminated); Q1 2026 revenue $15,288m; Sep 30, 2026 - $2B Summit oncology deal
Listing: NYSE ordinary shares (ticker AZN) since February 2, 2026; also listed on LSE and Nasdaq Stockholm; live quotes Oct 1-2, 2026 - no delisting

Frequently asked questions

What does AstraZeneca do?

AstraZeneca PLC (NYSE: AZN), based in Cambridge, England, is a global, science-led biopharmaceutical company. Per its Form 20-F for FY2025, revenue by therapy area: Oncology (Tagrisso, Imfinzi, Lynparza, Enhertu - the core growth driver); BioPharmaceuticals - Cardiovascular, Renal and Metabolism ($12,861m) and Respiratory and Immunology ($8,866m; Breztri, Fasenra, Tezspire, Saphnelo); Rare Disease (via Alexion); and Vaccines and Immune Therapies ($1,268m; FluMist, Beyfortus). Total revenue in FY2025 was $58,739m (+9%). Note: AstraZeneca voluntarily delisted its ADSs from Nasdaq on January 30, 2026 and began a direct listing of its $0.25 ordinary shares on the NYSE on February 2, 2026 (ticker AZN retained; the ADR programme was terminated).

Why does AstraZeneca pass this Shariah stock screen?

AstraZeneca passes all three gates of this Shariah stock screen. Gate 1 (business activity): 100% prescription-medicine revenue - no alcohol, tobacco, gambling, weapons, adult entertainment, pork, or conventional-finance segments. Gate 2 (debt): interest-bearing loans and borrowings of $27,819m are about 11.1% of its ~$250.4B market cap, below the ~33% ceiling. Gate 3 (non-compliant income): finance income of $360m is about 0.61% of FY2025 revenue ($58,739m), below the 5% ceiling. Result: PASS. This is a factual screen, not a religious ruling - consult a qualified scholar for personal rulings.

What is AstraZeneca's interest-bearing debt ratio?

Per AstraZeneca's Form 20-F 'Annual Report & Form 20-F Information 2025' (fiscal year ended December 31, 2025; filed with the SEC February 24, 2026; Commission File No. 001-11960), interest-bearing loans and borrowings were $3,104m (current) plus $24,715m (non-current) = $27,819m total. Against a market cap of about $250.4B (quoted September 30, 2026; cross-check: $157.70 x about 1.55 billion ordinary shares in issue = about $244B, October 2, 2026), debt / market cap is about 11.1% - below the ~33% ceiling. Cash and cash equivalents of $5,711m plus other investments ($30m + $2,223m) = $7,964m of cash/securities, about 3.2% of market cap. Gate 2 passes. Facts only.

How much interest income does AstraZeneca earn?

AstraZeneca's FY2025 Form 20-F reports finance income of $360m (2024: $458m; 2023: $344m) - returns on deposits and equity securities plus interest on tax balances (Note 4). $360m / FY2025 total revenue of $58,739m = about 0.61% of revenue, below the 5% non-compliant income ceiling. Third-party screener Zoya independently reports the same $360m figure at 0.61% of revenue. Gate 3 passes. Facts only.

Do Zoya, Musaffa, or ShariaPortfolio cover AstraZeneca?

Zoya covers AstraZeneca at zoya.finance/stocks/azn: 'As of September 2026, AZN is Shariah-compliant and therefore considered halal to invest in,' quoting interest income of $360m on revenue of $58,739m (0.61%); Zoya also lists AZN in its 'Top Rated Halal Stocks'. Musaffa covers AstraZeneca at musaffa.com/stock/AZN.L/: 'As of September 2026, AstraZeneca PLC is classified as halal' under AAOIFI methodology. ShariaPortfolio: no public AstraZeneca rating was located - honestly reported as no coverage found, not invented.

Sources

Screened 2026-10-02 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.

Screened with our two-gate Shariah screening methodology (business-activity gate, then AAOIFI-style financial ratios).